CN105732736A - Phenylpropanoid compound preparation method - Google Patents

Phenylpropanoid compound preparation method Download PDF

Info

Publication number
CN105732736A
CN105732736A CN201610154680.1A CN201610154680A CN105732736A CN 105732736 A CN105732736 A CN 105732736A CN 201610154680 A CN201610154680 A CN 201610154680A CN 105732736 A CN105732736 A CN 105732736A
Authority
CN
China
Prior art keywords
preparation
water
phenylpropanoids
methanol
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201610154680.1A
Other languages
Chinese (zh)
Other versions
CN105732736B (en
Inventor
李伏君
龚云
张鹏
夏博候
彭开锋
李亚梅
佘娜
赵威
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhuzhou Qianjin Pharmaceutical Co Ltd
Original Assignee
Zhuzhou Qianjin Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhuzhou Qianjin Pharmaceutical Co Ltd filed Critical Zhuzhou Qianjin Pharmaceutical Co Ltd
Priority to CN201610154680.1A priority Critical patent/CN105732736B/en
Publication of CN105732736A publication Critical patent/CN105732736A/en
Priority to PCT/CN2017/076455 priority patent/WO2017157260A1/en
Priority to US16/132,506 priority patent/US10329316B2/en
Application granted granted Critical
Publication of CN105732736B publication Critical patent/CN105732736B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/06—Separation; Purification
    • C07H1/08—Separation; Purification from natural products

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention relates to the technical field of medicines, discloses a phenylpropanoid compound preparation method and particularly relates to a phenylpropanoid compound separated from dry roots of Moghania macrophylla (Willd.) O.Ktze.. The phenylpropanoid compound is obtained by solvent extraction, column chromatography separation and preparative liquid phase separation and purification. The phenylpropanoid compound prepared by the preparation method is put forward for the first time and is high in purity.Experiments prove that the novel phenylpropanoid compound is capable of inhibiting content of inflammatory cytokines NO and expression of inflammatory cytokines TNF (tumor necrosis factor)-alpha and plays a role in inhibiting hydroxyl radicals (-OH) to further have anti-inflammatory effect and antioxidant activity and benefit treatment of various inflammatory diseases such as cervicitis, endometritis, pelvic inflammation, mastitis, sphagitis and/or arthritis, thereby being developed into novel medicines. The phenylpropanoid compound shown as structural formula (I) and pharmaceutically acceptable salts thereof are prepared.

Description

A kind of preparation method of phenylpropanoids
Technical field
The present invention relates to pharmaceutical technology field, more particularly, to the preparation method of a kind of phenylpropanoids.
Background technology
The constituent structure extracting isolated from natural drug is various, active significantly, and it is carried out isolated and purified, structure Modify, transform and complete synthesis, an always main thought of new drug development.
TNF-α: be a kind of can direct killing tumor cell and to normal cell without the cytokine of overt toxicity, be so far One of bioactie agent that the direct killing function of tumor that found till the present is the strongest, but its toxic and side effects is the tightest Weight.
IL-1 β: collaborative APC and the T cell activation of stimulating, promotion B cell proliferation and secretory antibody when local low concentration, enter Row immunomodulating.There is endocrine effect during a large amount of generation: induced liver acute phase protein synthesizes, cause heating and cachexia.
IL-6: mankind's IL-6 gene is positioned on No. 7 chromosome；IL-6 molecular weight is between 21～30KD.Main by list Core macrophage, Th2 cell, vascular endothelial cell, fibroblast produce.Activating B cell can be stimulated to breed, and secretion is anti- Body；Stimulate T cell propagation and CTL activation；Cell cultured supernatant synthesized acute phase albumen, participates in inflammatory reaction；Promote that hemocyte is sent out Educate.
IL-6 can be synthesized by various kinds of cell, including activation T cell and B cell, monocytes/macrophages, endotheliocyte, Epithelial cell and fibroblast etc..The target cell of IL-6 effect is a lot, thin including macrophage, hepatocyte, static T Born of the same parents, the B cell of activation and plasma cell etc.；Its biological effect is the most sufficiently complex.
OH is the reactive oxygen species of most activity in biosystem, can cause DNA in cell and organism, protein and fat Matter oxidative damage.
Macrophage can produce inflammation medium and participate in inflammatory reaction, and wherein, NO is the important cellular inflammation factor, NO Participating in multiple pathological processes, excessive NO can promote generation and the development of diseases associated with inflammation, and can also induce other inflammation The factor.
Therefore, seek a kind of new preparation method, from natural plants, separate the compound made new advances, to suppress cellular inflammation The content of factor NO and the expressional function of cellular inflammation factor TNF-α, the activity of suppression hydroxyl radical free radical (-OH), it is applied to inflammation The treatment of disease property disease, is necessary.
Radix Flemingiae Philippinensis medical material is that pulse family (Leguminosae) Moghania (Flemingl.Roxb. or Moghania) plant is big The dry root of leaf Radix Flemingiae Philippinensis (Moghania macrophylla (Willd.) O.Kuntze), is distributed mainly on the southeast in China Area.This plant Chinese Plants will (1995,41:313), Flora of Taiwan (1977,3:258), Hainan flora (1965, 2:311), " Chinese Higher plant illustrated handbook " (1972,2:510), China's main plant figure say (1955, pp707) and Guangzhou plant Will is all included in (1956, pp361).Radix Flemingiae Philippinensis medical material is the genuine medicinal materials of Guangxi province, and history is loaded in " Zhiwu Mingshi Tukao ", There is medication the most among the people basis.Its nature and flavor are sweet, micro-puckery, flat, have the effects such as removing damp-heat, are mainly used in treating rheumatic bone The gynaecopathia such as bitterly, traumatic injury, chronic nephritis, dysmenorrhea and leucorrhea be many.This medical material has recorded the most into version " middle traditional Chinese medicines in 2005 Allusion quotation " annex.
The composition that Flemingia macrophylla has been reported mainly has flavonoid, steroid, terpenoid, Anthraquinones, volatile oil composition, all has There is certain pharmacologically active.
Flemingia macrophylla pharmacologically active is various, reports the more neuroprotective that has, and antiinflammatory, antioxidation, to disease The anthelmintic action of pathogenic microorganism, parahormone effect, cytotoxicity, antibacterial action and immunological enhancement, antifatigue effect.
Radix Flemingiae Philippinensis is now widely used for the Chinese patent medicine of the type such as gynecological, rheumatic arthralgia and produces, such as FUKE QIANJIN PIAN, gynecological A thousand pieces of gold capsule, JINJI CHONGJI, JINJI JIAONANG etc., this type of Chinese patent medicine is mainly used in gynaecopathia, and (dysmenorrhea, cold uterus be infertile, uterus Sagging, pelvic inflammatory disease, mastitis, leucorrhea are many, blood deficiency in puerperal, arthralgia, waist and knee in puerperal, hypogalactia and breast ulcer etc.), weak anemia (woman anemia, deficient qi and blood and the after being ill deficiency of vital energy etc.).In recent years, what clinical report was more is that FUKE QIANJIN PIAN is scorching in treatment gynecological Effect in terms of disease.
At present, in the document of Radix Flemingiae Philippinensis, the document of report phenylpropanoids is few, finds a kind of new preparation side Method, isolates effective Phenylpropanoid Glycosides class noval chemical compound from natural plants, it is carried out isolated and purified, structural modification and synthesis, Developing new drug, is applied to the treatment of diseases associated with inflammation, significant.
Summary of the invention
It is an object of the invention to provide a kind of a kind of Phenylpropanoid Glycosides class of isolated from the dry root of Flemingia macrophylla The preparation method of compound, the compound being extracted isolated by this preparation method can suppress containing of cellular inflammation factor NO Amount and the expressional function of cellular inflammation factor TNF-α, have the inhibitory action of (-OH) to hydroxyl radical free radical, and then have anti- Inflammation and antioxidant activity, be of value to the treatment of various diseases associated with inflammation, this compound can be developed into new drug.
Specifically, the preparation method of phenylpropanoids of the present invention comprises the steps:
S1. the root taking Flemingia macrophylla is raw material, is dried, stripping and slicing, extracts through ethanol solution, is merged by extracting solution, dense It is reduced to, without alcohol taste, obtain extractum standby；
S2. being dissolved in water by gained extractum in step S1, use macroporous adsorptive resins that it is carried out eluting, eluant is Ethanol-water system, collects the eluent of front 3 column volumes, and named MM-1 is standby；
S3. the flow point MM-1 reversed material ODS column chromatography collected in step S2 being carried out eluting, eluant is first Alcohol-water system, 18 column volumes of eluting, collect the eluent of a flow point by every 3 column volumes, collect 6 flow points in order, It is respectively designated as MM-11, MM-12, MM-13, MM-14, MM-15, MM-16, standby；
S4. by the flow point MM-12 collected in step S3 with preparing liquid phase separation, flowing is methanol-water-acetic acid system mutually System, collects eluent by peak sequence, collects 7 flow points altogether, be respectively designated as MM-121, MM-122, MM-123, MM-124, MM-125, MM-126, MM-127, standby；
S5. being purified with preparing liquid phase by the flow point MM-125 collected in step S4, flowing is methanol-water-acetic acid system mutually System, collects eluent, obtains described phenylpropanoids after recrystallization.Described phenylpropanoids purity is 99.84%. Shown in the structural formula of described phenylpropanoids such as formula (1):
Preferably, in step S1, the concentration of ethanol solution is 50～80 volume %, more preferably ethanol solution concentration It is 60 volume %.
Preferably, in step S1, the extraction time of ethanol solution is 2～4 times, extracts 1～3 hour every time, the most excellent The extraction time electing ethanol solution as is 3 times, each 2 hours.
Preferably, in step S2, macroporous adsorbent resin uses D101 macroporous adsorbent resin.
Preferably, in step S2, ethanol with the volume ratio of water is: 0:100～15:85.
Preferably, in step S3, methanol is 20:80～30:70, more preferably 25:75 with the volume ratio of water.
Preferably, in step S4, the volume ratio of methanol-water-acetic acid is 10:90:0.01～35:65:0.01, the most excellent Elect 15:85:0.01 as.
Preferably, in step S4, preparative liquid chromatography post is YMC, 20mm*250mm, and flow rate of mobile phase is: 5～10ml/ Min, preferably flow velocity 5ml/min.
Preferably, in step S5, the volume ratio of methanol-water-acetic acid is 15:85:0.01.
Preferably, in step S5, preparative liquid chromatography post is YMC, 20mm*250mm, and flow rate of mobile phase is 5mL/min.
The present invention provides the phenylpropanoids that described preparation method prepares.
And the phenylpropanoids prepared for raw material through chemical synthesis process with described phenylpropanoids Salt.The structure of described salt is as shown in formula II or formula III:
Wherein, R is mineral acid, R1Or R2Or R3For any one in sulfonate radical, alkali metal ion or ammonium root or any two Plant or any three kinds.
Preferably, described mineral acid is hydrochloric acid, hydrobromic acid, Fluohydric acid., hydroiodic acid, sulphuric acid, nitric acid, carboxylic acid, phosphoric acid or breast Acid；Described sulfonate radical is the sulfonate radical with aryl；Described alkali metal ion be potassium ion, sodium ion, calcium ion, magnesium ion or Lithium ion.
Preferably, the sulfonate radical described in aryl is benzenesulfonic acid root or p-methyl benzenesulfonic acid root.
Preferably, described pharmaceutically acceptable salt is ammonium salt.
Beneficial effects of the present invention:
The present invention is new phenylpropanoids and pharmaceutically acceptable salt provides a kind of preparation method, first A kind of new phenylpropanoids of isolated from the dry root of Flemingia macrophylla, prepared compound can suppress cell The content of inflammatory factor NO and the expressional function of cellular inflammation factor TNF-α, the suppression with (-OH) to hydroxyl radical free radical is made With, and then there is antiinflammatory and antioxidant activity, can serve as such as cervicitis, endometritis, pelvic inflammatory disease, mastitis, pharyngolaryngitis And/or the medicine of the diseases associated with inflammation such as arthritis.
It is an object of the invention to from traditional prescriptions of Chinese medicine, by the prescription from FUKE QIANJIN PIAN and FUKE QIANJIN JIAONANG In, prepare a kind of new phenylpropanoids by solvent extraction, column chromatography for separation, preparation liquid phase separation, purification, and by real Checking is real, and it can apply to diseases associated with inflammation, such as cervicitis, endometritis, pelvic inflammatory disease, mastitis, pharyngolaryngitis and/or pass The treatment of the diseases such as joint is scorching.
Specifically, inventor by from FUKE QIANJIN PIAN, FUKE QIANJIN JIAONANG prescription, science chooses Flemingia macrophylla Dry root, by solvent extraction, column chromatography for separation, preparation liquid phase separation, purification, obtain Phenylpropanoid Glycosides class chemical combination of the present invention Thing, then carries out test cell line to this compound, measures it to cellular inflammation factor NO, TNF-α and hydroxyl radical free radical (-OH) Suppression degree, experiment shows, the NO content that LPS is caused in the range of concentration (6.88 12.38 μ g/mL) by this compound raises There is obvious inhibitory action, and show obvious dose-dependence.In the range of concentration (6.88 12.38 μ g/mL), energy Significantly inhibit Raw 264.7 cell and produce inflammatory factor TNF-α (p ＜ 0.05), and in significant dose-dependence, in concentration The OH content in the range of (4.13 12.38 μ g/mL) caused LPS raises obvious inhibitory action, and shows certain agent Amount dependence.
Accompanying drawing explanation
Fig. 1 is the hydrogen nuclear magnetic resonance spectrogram of phenylpropanoids of the present invention.
Fig. 2 is the carbon-13 nmr spectra figure of phenylpropanoids of the present invention.
Fig. 3 is that phenylpropanoids of the present invention affects figure to cytoactive.
Fig. 4 is the phenylpropanoids of the present invention inhibitory action figure to NO.
Fig. 5 is the phenylpropanoids of the present invention inhibitory action figure to TNF-α.
Fig. 6 is the phenylpropanoids of the present invention inhibitory action figure to IL-1 β.
Fig. 7 is the phenylpropanoids of the present invention inhibitory action figure to IL-6.
Fig. 8 is the phenylpropanoids of the present invention inhibitory action figure to OH.
Detailed description of the invention
Further illustrate the present invention below in conjunction with Figure of description and specific embodiment, but embodiment is not to the present invention Limit in any form.Unless stated otherwise, the present invention uses reagent, method and apparatus are the examination of the art routine Agent, method and apparatus.Unless stated otherwise, to be the art conventional commercial former for raw material used by the present embodiment and equipment Material and equipment.
The compound of the present invention is the phenylpropanoids shown in described formula I and formula II or formula III this change shown Compound pharmaceutically acceptable salt.This compound can use the method extracted with Flemingia macrophylla that the present invention provides for raw material Prepare, it is also possible to the structural formula provided according to the present invention combines the methods such as the chemosynthesis of employing this area and prepares.
As the salt of phenylpropanoids of the present invention, as long as pharmaceutically acceptable salt, can be enumerated as The inorganic acid salt formed with the mineral acid such as hydrochloric acid, hydrobromic acid, Fluohydric acid., hydroiodic acid, sulphuric acid, nitric acid, carboxylic acid, phosphoric acid, lactic acid；With The sulfonate that sulfonic acid is formed；The alkali metal salt formed with the alkali-metal hydroxide such as potassium, sodium, calcium, magnesium, lithium, is formed with ammonium Ammonium salt etc..
Phenylpropanoids of the present invention can be used as cervicitis, endometritis, pelvic inflammatory disease, mastitis, pharyngolaryngitis and/ Or the medicine of the diseases associated with inflammation such as arthritis.
The compounds of this invention can be used as pharmaceutical composition together with the adjuvant pharmaceutically allowed and/or carrier, it is also possible to In the case of adding the adjuvant that pharmaceutically allows and/or carrier with Radix Rosae Laevigatae, Fructus Zanthoxyli Dissiti, Caulis Spatholobi, Caulis Mahoniae, Herba Andrographis, One or more Chinese crude drugs or the combination of extract in Radix Angelicae Sinensis, Radix Codonopsis are used as pharmaceutical composition, and the compounds of this invention is all right Pharmaceutical composition it is used as together with other pharmaceutically acceptable active ingredient.
As pharmaceutical composition, can be tablet, capsule, powder, granule, pill, solution, suspensoid, syrup Agent, injection, ointment, suppository, spray etc..
Further, tablet can be the sugar-coat made in the case of adding the adjuvant and/or carrier pharmaceutically allowed Sheet, Film coated tablets, enteric coatings ply or two-ply, multilayer tablet.
Adjuvant and/or the carrier of the present invention can be such that
Make solid preparation, it is possible to use additive, such as sucrose, lactose, cellulose sugar, maltose alcohol, glucose, shallow lake Powder class, agar, alginates, chitin, chitosan class, pectin class, Radix Acaciae senegalis class, gelatin class, collagen class, cheese egg In vain, albumin, calcium phosphate, Sorbitol, glycine, glycerol, Polyethylene Glycol, sodium bicarbonate, Talcum etc..
Make semi-solid preparation, it is possible to use of animal or plant nature oils and fats (olive oil, Semen Maydis oil, Oleum Ricini etc.), mineral oil Fat (vaseline, white vaseline, solid paraffin etc.), wax class (Jojoba oil, Brazil wax, Cera Flava etc.), partial synthesis or complete The fatty acid glyceride (lauric acid, myristic acid, Palmic acid etc.) etc. of synthesis.
Make liquid preparation, can use additive, such as sodium chloride, glucose, Sorbitol, glycerol, olive oil, the third two Alcohol, ethanol etc..In the case of especially making injection, it is possible to use aseptic aqueous solution, such as normal saline, isotonic solution, oiliness Liquid, such as Oleum Sesami, soybean oil.Furthermore it is also possible to as required, and with suitable suspending agent, such as sodium carboxymethyl cellulose, nonionic Surfactant, cosolvent, such as benzyl benzoate, benzyl alcohol etc..
The amount of the effective ingredient of these preparations is 0.01～80 weight % of preparation, is suitably 1～50 weight %, dosage Symptom according to patient, body weight, age etc. are different and change.
The preparation of embodiment 1 phenylpropanoids
The present embodiment provides a kind of preparation method of phenylpropanoids shown in formula I, comprises the steps:
S1. take Flemingia macrophylla 50kg, with root as raw material, be dried, be cut into small pieces.Alcohol reflux through 8 times amount 60% Extract 3 times, each 2 hours, extracting solution is merged, is concentrated into without alcohol taste, obtains extractum standby；
S2. the extractum after concentrating in step S1 is dissolved in 10L water, uses D101 macroporous adsorptive resins to wash it De-, eluant is water, 3 column volumes of eluting, collection eluent, and named MM-1 is standby；
S3. with anti-phase ODS column chromatography, the flow point MM-1 collected in step S2 being carried out eluting, eluant is methanol-water System, its volume ratio is 25:75,18 column volumes of eluting, collects the eluent of a flow point by every 3 column volumes, in order Collect 6 flow points, be respectively designated as: MM-11, MM-12, MM-13, MM-14, MM-15, MM-16 are standby；
S4. by the flow point MM-12 collected in step S3 with preparing liquid phase separation, preparative liquid chromatography post is: YMC, 20mm*250mm, flow velocity: 5ml/min, flowing is methanol-water-acetic acid system mutually, methanol: water: the volume ratio of acetic acid is 25:75: 0.01, collect eluent by peak sequence, collect 7 flow points altogether, be respectively designated as MM-121, MM-122, MM-123, MM- 124, MM-125, MM-126, MM-127, standby；
S5. being purified with preparing liquid phase by the flow point MM-125 collected in step S4, preparative liquid chromatography post is: YMC, 20mm*250mm, flow velocity: 5ml/min, flowing is methanol-water-acetic acid system mutually, methanol: water: the volume ratio of acetic acid is 15:85: 0.01, collect eluent, after recrystallization, obtain described phenylpropanoids.
The preparation of embodiment 2 phenylpropanoids
The present embodiment provides a kind of preparation method of phenylpropanoids shown in formula I, comprises the steps:
S1. take Flemingia macrophylla 40kg, with root as raw material, be dried, be cut into small pieces.Alcohol reflux through 6 times amount 50% Extract 2 times, each 1 hour, extracting solution is merged, is concentrated into without alcohol taste, obtains extractum standby；
S2. the extractum after concentrating in step S1 is dissolved in 5L water, uses D101 macroporous adsorptive resins to wash it De-, eluant is ethanol and the volume ratio of water is 15:85,3 column volumes of eluting, collects eluent, and named MM-1 is standby；
S3. with anti-phase ODS column chromatography, the flow point MM-1 collected in step S2 being carried out eluting, eluant is methanol-water System, its volume ratio is 20:80,18 column volumes of eluting, collects the eluent of a flow point by every 3 column volumes, in order Collect 6 flow points, be respectively designated as: MM-11, MM-12, MM-13, MM-14, MM-15, MM-16 are standby；
S4. by the flow point MM-12 collected in step S3 with preparing liquid phase separation, preparative liquid chromatography post is: YMC, 20mm*250mm, flow velocity: 10ml/min, flowing is methanol-water-acetic acid system mutually, methanol: water: the volume ratio of acetic acid is 35: 65:0.01, collects eluent by peak sequence, collects 7 flow points altogether, be respectively designated as MM-121, MM-122, MM-123, MM- 124, MM-125, MM-126, MM-127, standby；
S5. being purified with preparing liquid phase by the flow point MM-125 collected in step S4, preparative liquid chromatography post is: YMC, 20mm*250mm, flow velocity: 5ml/min, flowing is methanol-water-acetic acid system mutually, methanol: water: the volume ratio of acetic acid is 15:85: 0.01, collect eluent, after recrystallization, obtain described phenylpropanoids.
The preparation of embodiment 3 phenylpropanoids
The present embodiment provides a kind of preparation method of phenylpropanoids shown in formula I, comprises the steps:
S1. take Flemingia macrophylla 60kg, with root as raw material, be dried, be cut into small pieces.The alcohol reflux of 7 times amount 70% carries Take 4 times, each 3 hours, extracting solution is merged, is concentrated into without alcohol taste, obtains extractum standby；
S2. the extractum after concentrating in step S1 is dissolved in 8L water, uses D101 macroporous adsorptive resins to wash it De-, eluant is ethanol and the volume ratio of water is 10:90,3 column volumes of eluting, collects eluent, and named MM-1 is standby；
S3. with anti-phase ODS column chromatography, the flow point MM-1 collected in step S2 being carried out eluting, eluant is methanol-water System, its volume ratio is 30:70,18 column volumes of eluting, collects the eluent of a flow point by every 3 column volumes, in order Collect 6 flow points, be respectively designated as: MM-11, MM-12, MM-13, MM-14, MM-15, MM-16 are standby；
S4. by the flow point MM-12 collected in step S3 with preparing liquid phase separation, preparative liquid chromatography post is: YMC, 20mm*250mm, flow velocity: 10ml/min, flowing is methanol-water-acetic acid system mutually, methanol: water: the volume ratio of acetic acid is 30: 70:0.01, collects eluent by peak sequence, collects 7 flow points altogether, be respectively designated as MM-121, MM-122, MM-123, MM- 124, MM-125, MM-126, MM-127, standby；
S5. being purified with preparing liquid phase by the flow point MM-125 collected in step S4, preparative liquid chromatography post is: YMC, 20mm*250mm, flow velocity: 5ml/min, flowing is methanol-water-acetic acid system mutually, methanol: water: the volume ratio of acetic acid is 15:85: 0.01, collect eluent, after recrystallization, obtain described phenylpropanoids.
The preparation of embodiment 4 phenylpropanoids
The present embodiment provides a kind of preparation method of phenylpropanoids shown in formula I, comprises the steps:
S1. take Flemingia macrophylla 50kg, with root as raw material, be dried, be cut into small pieces.The alcohol reflux of 8 times amount 60% carries Take 2 times, each 1.5 hours, extracting solution is merged, is concentrated into without alcohol taste, obtains extractum standby；
S2. the extractum after concentrating in step S1 is dissolved in 6L water, uses D101 macroporous adsorptive resins to wash it De-, eluant is ethanol and the volume ratio of water is 5:95,3 column volumes of eluting, collects eluent, and named MM-1 is standby；
S3. with anti-phase ODS column chromatography, the flow point MM-1 collected in step S2 being carried out eluting, eluant is methanol-water System, its volume ratio is 25:75,18 column volumes of eluting, collects the eluent of a flow point by every 3 column volumes, in order Collect 6 flow points, be respectively designated as: MM-11, MM-12, MM-13, MM-14, MM-15, MM-16 are standby；
S4. by the flow point MM-12 collected in step S3 with preparing liquid phase separation, preparative liquid chromatography post is: YMC, 20mm*250mm, flow velocity: 10ml/min, flowing is methanol-water-acetic acid system mutually, methanol: water: the volume ratio of acetic acid is 25: 75:0.01, collects eluent by peak sequence, collects 7 flow points altogether, be respectively designated as MM-121, MM-122, MM-123, MM- 124, MM-125, MM-126, MM-127, standby；
S5. being purified with preparing liquid phase by the flow point MM-125 collected in step S4, preparative liquid chromatography post is: YMC, 20mm*250mm, flow velocity: 5ml/min, flowing is methanol-water-acetic acid system mutually, methanol: water: the volume ratio of acetic acid is 15:85: 0.01, collect eluent, after recrystallization, obtain described phenylpropanoids.
The preparation of embodiment 5 phenylpropanoids
The present embodiment provides a kind of preparation method of phenylpropanoids shown in formula I, comprises the steps:
S1. take Flemingia macrophylla 50kg, with root as raw material, be dried, be cut into small pieces.The alcohol reflux of 8 times amount 80% carries Take 2 times, each 1.5 hours, extracting solution is merged, is concentrated into without alcohol taste, obtains extractum standby；
S2. the extractum after concentrating in step S1 is dissolved in 6L water, uses D101 macroporous adsorptive resins to wash it De-, eluant is ethanol and the volume ratio of water is 10:90,3 column volumes of eluting, collects eluent, and named MM-1 is standby；
S3. with anti-phase ODS column chromatography, the flow point MM-1 collected in step S2 being carried out eluting, eluant is methanol-water System, its volume ratio is 28:72,18 column volumes of eluting, collects the eluent of a flow point by every 3 column volumes, in order Collect 6 flow points, be respectively designated as: MM-11, MM-12, MM-13, MM-14, MM-15, MM-16 are standby；
S4. by the flow point MM-12 collected in step S3 with preparing liquid phase separation, preparative liquid chromatography post is: YMC, 20mm*250mm, flow velocity: 10ml/min, flowing is methanol-water-acetic acid system mutually, methanol: water: the volume ratio of acetic acid is 10: 90:0.01, collects eluent by peak sequence, collects 7 flow points altogether, be respectively designated as MM-121, MM-122, MM-123, MM- 124, MM-125, MM-126, MM-127, standby；
S5. being purified with preparing liquid phase by the flow point MM-125 collected in step S4, preparative liquid chromatography post is: YMC, 20mm*250mm, flow velocity: 5ml/min, flowing is methanol-water-acetic acid system mutually, methanol: water: the volume ratio of acetic acid is 15:85: 0.01, collect eluent, after recrystallization, obtain described phenylpropanoids.
Compound embodiment 1 to embodiment 5 prepared carries out mass spectrum, proton nmr spectra, carbon-13 nmr spectra Detection, result prove gained compound be: 3 ', 5 '-dihydroxy-4 '-glucosyl group-phenyl-3-hydroxy methyl propionate.Its knot Structure formula is as shown in formula I:
Its mass spectrum, proton nmr spectra, carbon-13 nmr spectra spectral data as follows:
HR-ESIMS shows [M+Na]+for m/z 399.1889, and in conjunction with nuclear-magnetism feature, can obtain molecular formula is C15H20O11, no Saturation is 6.
1H-NMR(600MHz,CD3OD):6.60(d,1H),6.47(d,1H),4.95(s,1H),4.94(m,2H),3.00- 4.00(glc-H),2.71(m,2H)。
13C-NMR(150MHz,CD3OD):170.5(C-1),150.7(C-1'),150.2(C-4'),135.5(C-3', 5'),114.7(C-2',6'),101.2(C-1”),61.5-77.8(C2”-C6”),61.1(C-2),38.69(C-3)。
The preparation of embodiment 6 phenylpropanoids salt
The preparation of phenylpropanoids hydrochlorate:
This compound methanol solution will drip saturated hydrochloric acid to dripping acetonitrile under pH value 2-3, stirring under stirring, sucking filtration, It is dried to obtain white powder solid, is the hydrochlorate of phenylpropanoids.
The preparation of phenylpropanoids sulfonate:
Alkali-metal hydroxide is added in the reaction system containing this compound, solvent, sulfonic acid, neutral oil and accelerator Thing, adds solvent, lower alcohol and kicker, is passed through carbon dioxide, isolated white powder solid, is Phenylpropanoid Glycosides class The sulfonate of compound.
Phenylpropanoids potassium salt or the preparation of sodium salt:
KOH or N in ethanol will be dissolved inaOH adds in this phenylpropanoids, the lower heating reflux reaction of stirring, cold system Room temperature, drips acetonitrile, sucking filtration, is dried to obtain white solid, is potassium salt or the sodium salt of this phenylpropanoids under stirring.
The preparation of phenylpropanoids ammonium salt:
This compound methanol solution will drip saturated ammonia to dripping acetonitrile under pH value 9-11, stirring under stirring, sucking filtration, It is dried to obtain white solid, is the ammonium salt of phenylpropanoids.
The spectral data of above-mentioned phenylpropanoids salt:
Phenylpropanoids hydrochlorate: ESIMS shows m/z 412.67, nuclear-magnetism feature1H-NMR(600MHz,CD3OD) :1H-NMR(600MHz,CD3OD):6.63(d,1H),6.49(d,1H),5.05(s,1H),4.98(m,2H),3.00-4.00 (glc-H),2.74(m,2H)。
Phenylpropanoids sulfonate: ESIMS is shown as m/z 504.28, nuclear-magnetism feature1H-NMR(600MHz, CD3OD):1H-NMR(600MHz,CD3OD):6.55(d,1H),6.36(d,1H),4.90(s,1H),4.91(m,2H),3.00- 4.00(glc-H),2.51(m,2H)。
Phenylpropanoids potassium salt or sodium salt:
Potassium salt ESIMS shows m/z 452.19, nuclear-magnetism feature1H-NMR(600MHz,CD3OD):6.70(d,1H),6.57 (d,1H),4.94(s,1H),4.91(m,2H),3.00-4.00(glc-H),2.70(m,2H)。
Sodium salt ESIMS shows m/z 420.19, nuclear-magnetism feature1H-NMR(600MHz,CD3OD):6.56(d,1H),6.46 (d,1H),4.74(s,1H),4.51(m,2H),3.00-4.00(glc-H),2.60(m,2H)。
Phenylpropanoids ammonium salt: ESIMS shows m/z 406.57, nuclear-magnetism feature1H-NMR(600MHz,CD3OD):1H-NMR(600MHz,CD3OD):6.63(d,1H),6.33(d,1H),4.94(s,1H),4.91(m,2H),3.00-4.00 (glc-H),2.77(m,2H)。
Shown in the structural formula such as formula IV of above-mentioned phenylpropanoids salt～formula (VIII).
Wherein, formula IV is the phenylpropanoids hydrochlorate prepared, and formula (V) is the Phenylpropanoid Glycosides prepared The one of which sulfonate of compounds, formula VI is the one of which potassium salt of the phenylpropanoids prepared, formula (VII) the one of which sodium salt of the phenylpropanoids for preparing, formula (VIII) is the phenylpropanoids prepared One of which ammonium salt.
Experimental example 7 application test
RAW 264.7 oxidative macrophage that LPS is induced by compound of the present invention and salt stress be with the shadow of inflammation Ring.(in order in experimentation, record is convenient, below phenylpropanoids of the present invention is numbered: medicine MM-125, The most heretofore described medicine MM-125 i.e. refers to phenylpropanoids shown in formula I of the present invention or it is pharmaceutically acceptable Salt.)
1 materials and methods
1.1 medicines and instrument
Lipopolysaccharide (lipopolysaccharide, LPS), MTT is purchased from Sigma company；Mouse macrophage Raw264.7 Purchased from the refined cell bank in Hunan；PBS；DMEM high glucose medium, hyclone, penicillin and streptomycin；Full-automatic microplate reader；Constant temperature CO2Incubator.
Mice IL-1β (IL-1-β) ELISA detection kit, lot number: 2014/06 (96T)；Little mIL6 (IL-6) ELISA detection kit, lot number: 2014/06 (96T)；Murine tumor necrosis factor-α (TNF-α) ELISA detects examination Agent box, lot number: 2014/06 (96T)；Mouse nitrous oxide (NO) ELISA detection kit, lot number: 2014/10 (96T)；Mice Hydroxyl radical free radical (OH) ELISA detection kit, lot number: 2014/10 (96T).
Prepared by 1.2 medicines
First dissolve with a small amount of DMSO, be then diluted to certain concentration with DMEM, make DMSO content in final concentration be less than 1‰。
1.3 cells are cultivated
Mouse macrophage Raw 264.7 be incubated at containing 10% heat inactivation (56 DEG C, 30min) hyclone (FBS), 10U/mL penicillin sodium, 100 μ g/mL streptomycins DMEM culture medium in, 37 DEG C, 5%CO2Constant incubator is hatched growth.
1.4 cell viabilities measure
Cell viability is measured by mtt assay.Cell is made cell suspension inoculation incubate in 96 orifice plates (1 × 104/hole) Educating 24h, resynchronization 24h, then the medicine of variable concentrations is acted on cell 2h, then adding LPS (30 μ g/mL) stimulates 24h, inhales and abandons former culture medium, and every hole adds the MTT (0.5mg/mL) of 100 μ L and continues to hatch 4h, inhales and abandons culture medium, and every hole adds The DMSO of 150 μ L, shaking table shaking 10min, measure absorbance at 490nm.
1.5NO assay
Raw 264.7 cell is inoculated in 96 orifice plate 24h, resynchronization 24h, is then acted on carefully by the medicine of variable concentrations Born of the same parents 2h, then adding LPS (30 μ g/mL) stimulates 24h, finally collects supernatant, and is centrifuged 5min in 10000rpm, on subpackage It is placed in clearly-80 DEG C to save backup.By mice NO kit measurement NO content.
1.6 inflammatory factor TNF-α, IL-1 β, IL-6 measure
Sample takes 1.5 samples prepared for subsequent inflammation factor determination.Cell generation TNF-α, IL-1 β, IL-6's Amount is by mice TNF-α, and IL-1 β, IL-6 test kit measures.
1.7OH assay
Sample takes 1.5 samples prepared for OH factor determination.By OH kit measurement content.
1.8 statistical analysis
Using SPSS17.0 software, experimental data is so that (x ± s represents；The data obtained is by with one factor analysis of variance, square Difference homogeneous LSD checks, and heterogeneity of variance Dunnett T3 checks.
2 experimental results
2.1 cell viability
The impact of cell viability is evaluated by medicine by mtt assay.As it is shown on figure 3, medicine MM-125 is at 1.37-12.37 μ In g/mL concentration range, Raw 264.7 cell viability is had no significant effect；Therefore the drug level pair under this range of concentrations It is suitable in subsequent experimental.
The generation of 2.2 Drug inhibition NO
As shown in Figure 4, by LPS stimulate Raw 264.7 cell, its produce NO (48.66 ± 1.66IU/mL) content with just Often organize NO (29.05 ± 0.85IU/mL) and compare significantly raised (p ＜ 0.01).Medicine MM-125 is at concentration (6.88 ± 12.38 μ g/ ML) the NO content in the range of caused LPS raises obvious inhibitory action, and shows obvious dose-dependence.
2.3 Drug inhibition TNF-α, the generation of IL-1 β, IL-6
As shown in Figures 5 to 7, Raw 264.7 cell, Raw 264.7 cellular inflammation factor TNF-α are stimulated by LPS (127.98 ± 4.65pg/mL), IL-1 β (347.55 ± 9.56pg/mL), IL-6 (201.67 ± 10.32pg/mL) content with just Often organize TNF-α (67.12 ± 4.00pg/mL), IL-1 β (160.88 ± 13.10pg/mL), IL-6 (111.13 ± 8.06pg/mL) Compare content significantly raised (p ＜ 0.01)；Illustrate that LPS can stimulate Raw 264.7 cell to produce a large amount of inflammatory factors.
Medicine MM-125 can significantly inhibit Raw 264.7 cell in the range of concentration (6.88-12.38 μ g/mL) and produce Inflammatory factor TNF-α (p ＜ 0.05), and in significant dose-dependence；At various concentrations, it is impossible to significantly inhibit Raw 264.7 cells produce IL-1 β, IL-6 (p ＞ 0.05).
The generation of 2.4 Drug inhibition OH
As shown in Figure 8, by LPS stimulate Raw 264.7 cell, its produce OH (106.00 ± 3.90ng/mL) content with Normal group OH (64.62 ± 2.18ng/mL) compares significantly raised (p ＜ 0.01).
The OH content that LPS is caused in the range of concentration (4.13-12.38 μ g/mL) by medicine MM-125 raises to be had significantly Inhibitory action, and show certain dose-dependence.
This experiment, through In vitro culture, have studied medicine MM-125 to mouse macrophage NO, TNF-α, IL-1 β, IL-6, OH The impact generated.
The medicine MM-125 obvious inhibiting effect that has to factor NO, and TNF-α is also had certain inhibitory action, But it without obvious inhibiting effect, illustrates that it has certain anti-inflammatory activity to IL-1 β, IL-6；Having of OH is significantly pressed down by it Effect processed, illustrates that it has preferable antioxidant activity.
Embodiment 8
The preparation of tablet: first prepare the phenylpropanoids shown in formula I as embodiment 1 method, and utilize this change Compound and mineral acid (example hydrochloric acid, hydrobromic acid, Fluohydric acid., hydroiodic acid, sulphuric acid, nitric acid, carboxylic acid, phosphoric acid, lactic acid) or sulfonic acid or alkali The salt that the hydroxide (such as potassium hydroxide, sodium hydroxide, calcium hydroxide, magnesium hydroxide, Lithium hydrate) of metal or ammonium are made, presses This compound or its any one salt add excipient, pelletizing press sheet with excipient weight than the ratio for 1:10.
Embodiment 9
The preparation of powder: first prepare the phenylpropanoids shown in formula I as embodiment 1 method, and utilize this change Compound and mineral acid (example hydrochloric acid, hydrobromic acid, Fluohydric acid., hydroiodic acid, sulphuric acid, nitric acid, carboxylic acid, phosphoric acid, lactic acid) or sulfonic acid or alkali The salt that the hydroxide (such as potassium hydroxide, sodium hydroxide, calcium hydroxide, magnesium hydroxide, Lithium hydrate) of metal or ammonium are made, presses Conventional powder preparation method makes powder.
Embodiment 10
Capsule or the preparation of granule: first prepare the phenylpropanoids shown in formula I as embodiment 1 method, with And utilize this compound and mineral acid (example hydrochloric acid, hydrobromic acid, Fluohydric acid., hydroiodic acid, sulphuric acid, nitric acid, carboxylic acid, phosphoric acid, lactic acid) Or sulfonic acid or alkali-metal hydroxide (such as potassium hydroxide, sodium hydroxide, calcium hydroxide, magnesium hydroxide, Lithium hydrate) or ammonium The salt made, adds excipient with excipient weight than the ratio for 1:10 in this compound or its any one salt, makes glue Wafer or granule.
Embodiment 11
The preparation of injection: first prepare the phenylpropanoids shown in formula I as embodiment 1 method, and utilization should Compound and mineral acid (example hydrochloric acid, hydrobromic acid, Fluohydric acid., hydroiodic acid, sulphuric acid, nitric acid, carboxylic acid, phosphoric acid, lactic acid) or sulfonic acid or The salt that alkali-metal hydroxide (such as potassium hydroxide, sodium hydroxide, calcium hydroxide, magnesium hydroxide, Lithium hydrate) or ammonium are made, Water for injection routinely, fine straining, injection is made in embedding sterilizing.
Embodiment 12
A kind of pharmaceutical composition, prepares the phenylpropanoids shown in formula I containing embodiment 1 method, and utilizes This compound and mineral acid (example hydrochloric acid, hydrobromic acid, Fluohydric acid., hydroiodic acid, sulphuric acid, nitric acid, carboxylic acid, phosphoric acid, lactic acid) or sulfonic acid Or alkali-metal hydroxide (such as potassium hydroxide, sodium hydroxide, calcium hydroxide, magnesium hydroxide, Lithium hydrate) or ammonium make Salt, and the powder that Radix Rosae Laevigatae, Fructus Zanthoxyli Dissiti, Caulis Spatholobi, Caulis Mahoniae, Herba Andrographis, Radix Angelicae Sinensis, Radix Codonopsis are made, and adjuvant.
Embodiment 13
A kind of pharmaceutical composition, prepares the phenylpropanoids shown in formula I, and Fructus Rosae Laevigatae containing embodiment 1 method The powder that root, Fructus Zanthoxyli Dissiti, Caulis Spatholobi, Caulis Mahoniae, Herba Andrographis, Radix Angelicae Sinensis, Radix Codonopsis are made, and adjuvant.
Embodiment 14
A kind of pharmaceutical composition, prepares the phenylpropanoids shown in formula I, and Fructus Rosae Laevigatae containing embodiment 1 method Root, Fructus Zanthoxyli Dissiti, Caulis Spatholobi, Caulis Mahoniae, Herba Andrographis, Radix Angelicae Sinensis, the extract of Radix Codonopsis, and adjuvant.Extract is by patent announcement number CN1078079C、CN1170549C、CN1158087C、CN1330335C、CN1296071C、CN1321631C、CN1296072C、 In any one of CN1296073C or several patent documents, extracting method prepares.
Embodiment 15
A kind of pharmaceutical composition, prepares the phenylpropanoids shown in formula I containing embodiment 1 method, and utilizes This compound and mineral acid (example hydrochloric acid, hydrobromic acid, Fluohydric acid., hydroiodic acid, sulphuric acid, nitric acid, carboxylic acid, phosphoric acid, lactic acid) or sulfonic acid Or alkali-metal hydroxide (such as potassium hydroxide, sodium hydroxide, calcium hydroxide, magnesium hydroxide, Lithium hydrate) or ammonium make Salt, and Radix Rosae Laevigatae, Fructus Zanthoxyli Dissiti, Caulis Spatholobi, Caulis Mahoniae, Herba Andrographis, Radix Angelicae Sinensis, the extract of Radix Codonopsis, and adjuvant.Extract be by Patent announcement CN1078079C, CN1170549C, CN1158087C, CN1330335C, CN1296071C, CN1321631C, In any one of CN1296072C, CN1296073C or several patent documents, extracting method prepares.
The ultimate principle of the present invention and principal character and the advantage of the present invention have more than been shown and described.The technology of this area Personnel, it should be appreciated that the present invention is not restricted to the described embodiments, simply illustrating this described in above-described embodiment and description The principle of invention, without departing from the spirit and scope of the present invention, the present invention also has various changes and modifications, and this is to this Being apparent from for skilled person, these changes and improvements both fall within scope of the claimed invention.This Bright claimed scope is defined by appending claims and equivalent thereof.

Claims (10)

1. the preparation method of a phenylpropanoids, it is characterised in that the structural formula of phenylpropanoids such as formula I institute Show,
(I)；
Described preparation method comprises the steps:
S1. the root taking Flemingia macrophylla is raw material, is dried, stripping and slicing, extracts through ethanol solution, is merged by extracting solution, is concentrated into Taste without alcohol, obtains extractum standby；
S2. being dissolved in water by gained extractum in step S1, use macroporous adsorptive resins that it is carried out eluting, eluant is second Alcohol-water system, collects the eluent of front 3 column volumes, and named MM-1 is standby；
S3. the flow point MM-1 reversed material ODS column chromatography collected in step S2 being carried out eluting, eluant is methanol-water System, 18 column volumes of eluting, collect the eluent of a flow point by every 3 column volumes, collect 6 flow points in order, respectively Named MM-11, MM-12, MM-13, MM-14, MM-15, MM-16, standby;
S4. by the flow point MM-12 collected in step S3 with preparing liquid phase separation, flowing is methanol-water-acetic acid system mutually, presses Peak sequence collects eluent, collects 7 flow points altogether, is respectively designated as MM-121, MM-122, MM-123, MM-124, MM- 125, MM-126, MM-127, standby；
S5. being purified with preparing liquid phase by the flow point MM-125 collected in step S4, flowing is methanol-water-acetic acid system mutually, receives Collection eluent, obtains described phenylpropanoids after recrystallization.
Preparation method the most according to claim 1, it is characterised in that: in step S1, the concentration of ethanol solution is 50 ~ 80 bodies Long-pending %, preferably ethanol solution concentration are 60 volume %.
Preparation method the most according to claim 1, it is characterised in that: in step S1, the extraction time of ethanol is 2 ~ 4 times, Extracting 1 ~ 3 hour, the preferably extraction time of ethanol is 3 times, each 2 hours every time.
Preparation method the most according to claim 1, it is characterised in that: in step S2, macroporous adsorbent resin uses D101 big Macroporous adsorbent resin.
Preparation method the most according to claim 1, it is characterised in that: in step S2, ethanol is 0:100 with the volume ratio of water ~15:85。
Preparation method the most according to claim 1, it is characterised in that: in step S3, eluant methanol and the volume ratio of water For 20:80 ~ 30:70, preferably 25:75.
Preparation method the most according to claim 1, it is characterised in that: in step S4, the volume ratio of methanol-water-acetic acid is 10:90:0.01 ~ 35:65:0.01, preferably 15:85:0.01.
Preparation method the most according to claim 1, it is characterised in that: in step S4, the chromatographic column of preparation liquid phase is YMC, 20mm*250mm, flow rate of mobile phase is 5 ~ 10mL/min, preferably flow velocity 5mL/min.
Preparation method the most according to claim 1, it is characterised in that in step S5, the volume ratio of methanol-water-acetic acid is 15:85:0.01。
Preparation method the most according to claim 1, it is characterised in that: in step S5, the chromatographic column of preparation liquid phase is YMC, 20mm*250mm, flow rate of mobile phase is 5mL/min.
CN201610154680.1A 2016-03-17 2016-03-17 A kind of preparation method of phenylpropanoids Active CN105732736B (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN201610154680.1A CN105732736B (en) 2016-03-17 2016-03-17 A kind of preparation method of phenylpropanoids
PCT/CN2017/076455 WO2017157260A1 (en) 2016-03-17 2017-03-13 Phenylpropanoid and preparation method and application thereof
US16/132,506 US10329316B2 (en) 2016-03-17 2018-09-17 Phenylpropanoid compound and preparation method and use thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610154680.1A CN105732736B (en) 2016-03-17 2016-03-17 A kind of preparation method of phenylpropanoids

Publications (2)

Publication Number Publication Date
CN105732736A true CN105732736A (en) 2016-07-06
CN105732736B CN105732736B (en) 2018-11-16

Family

ID=56250773

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610154680.1A Active CN105732736B (en) 2016-03-17 2016-03-17 A kind of preparation method of phenylpropanoids

Country Status (1)

Country Link
CN (1) CN105732736B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017157260A1 (en) * 2016-03-17 2017-09-21 株洲千金药业股份有限公司 Phenylpropanoid and preparation method and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102274341A (en) * 2010-06-10 2011-12-14 上海中医药大学 Extracting and refining process for medicinal components of figwort root
CN102631390A (en) * 2012-04-12 2012-08-15 贵州师范大学 Preparation method of periploca forrestii schltr extract as well as product and application of periploca forrestii schltr extract
CN104529984A (en) * 2014-12-25 2015-04-22 株洲千金药业股份有限公司 Method for extracting genistin from largeleaf flemingia

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102274341A (en) * 2010-06-10 2011-12-14 上海中医药大学 Extracting and refining process for medicinal components of figwort root
CN102631390A (en) * 2012-04-12 2012-08-15 贵州师范大学 Preparation method of periploca forrestii schltr extract as well as product and application of periploca forrestii schltr extract
CN104529984A (en) * 2014-12-25 2015-04-22 株洲千金药业股份有限公司 Method for extracting genistin from largeleaf flemingia

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017157260A1 (en) * 2016-03-17 2017-09-21 株洲千金药业股份有限公司 Phenylpropanoid and preparation method and application thereof
US10329316B2 (en) 2016-03-17 2019-06-25 Qianjin Pharmaceutical Co., Ltd. Phenylpropanoid compound and preparation method and use thereof

Also Published As

Publication number Publication date
CN105732736B (en) 2018-11-16

Similar Documents

Publication Publication Date Title
CN105884841B (en) A kind of preparation method of phenylpropanoids
CN105732736B (en) A kind of preparation method of phenylpropanoids
CN105708845B (en) A kind of application of phenylpropanoids and its pharmaceutically acceptable salt in the drug for preparing treatment diseases associated with inflammation
CN105663150B (en) A kind of application of phenylpropanoids and its pharmaceutically acceptable salt in the drug for preparing treatment diseases associated with inflammation
CN106046071B (en) A kind of preparation method of phenylpropanoids
CN105777821B (en) Phenylpropanoids and its pharmaceutically acceptable salt and pharmaceutical composition
CN106046072B (en) Phenylpropanoids and its pharmaceutically acceptable salt and pharmaceutical composition
CN106074579B (en) A kind of application of phenylpropanoids in the drug for preparing treatment diseases associated with inflammation
CN101367802B (en) Beta-kabarin alkaloids in quassia wood, preparation method and application thereof
CN105669792B (en) A kind of preparation method of phenylpropanoids
CN105601681B (en) A kind of preparation method of phenylpropanoids
CN105693789B (en) A kind of preparation method of phenylpropanoids
CN106074583B (en) A kind of application of phenylpropanoids and its pharmaceutically acceptable salt in the drug for preparing treatment diseases associated with inflammation
CN105687217B (en) A kind of application of phenylpropanoids and its pharmaceutically acceptable salt in the drug of preparation treatment diseases associated with inflammation
CN105646613B (en) Phenylpropanoids and its pharmaceutically acceptable salt and pharmaceutical composition
CN105582016B (en) A kind of application of phenylpropanoids in the drug for preparing treatment diseases associated with inflammation
CN105663149B (en) A kind of application of phenylpropanoids and its pharmaceutically acceptable salt in the drug for preparing treatment diseases associated with inflammation
CN106046073B (en) A kind of preparation method of phenylpropanoids
CN105601682B (en) Phenylpropanoids and its pharmaceutically acceptable salt and pharmaceutical composition
CN105732737B (en) A kind of phenylpropanoids and its pharmaceutical composition
CN105646614B (en) Phenylpropanoids and its pharmaceutically acceptable salt and pharmaceutical composition
CN105820197B (en) A kind of phenylpropanoids and its pharmaceutical composition
US10329316B2 (en) Phenylpropanoid compound and preparation method and use thereof
KR20070088984A (en) Araliaceae extracts compositions for treating or preventing inflammatory diseases
CN115487178A (en) Application of luteolin in preparation of medicine for treating or preventing psoriasis

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant